环磷酰胺联合糖皮质激素治疗特发性肺纤维化急性加重(EXAFIP):一项随机双盲安慰剂对照3期试验
EXAFIP是一项在法国31家医院35个科室开展的双盲安慰剂对照3期试验,纳入120例IPF急性加重或疑似急性加重成人患者,随机接受静脉环磷酰胺脉冲(600 mg/m2,第0、15、30、60天)联合标准大剂量糖皮质激素或安慰剂。6个月不良事件两组相似,感染为主要不良事件。结论提供反对在此类患者中使用静脉环磷酰胺的证据。
要点
- 6个月不良事件两组相似(环磷酰胺组42% vs 安慰剂组51%),总体感染为主要不良事件(33% vs 36%)。
- 研究排除了接受机械通气、活动性感染、活动性癌症或已登记肺移植等待名单的患者。
适用人群与场景
- 成人(≥18岁)IPF急性加重或疑似急性加重患者,来自法国31家医院35个科室。
- 排除接受机械通气、活动性感染、活动性癌症或已登记肺移植等待名单的患者。
- 所有患者均接受标准化大剂量糖皮质激素治疗。
诊断标准与关键阈值
- 原文未提及
处置流程与药物剂量
- 所有患者接受标准化大剂量糖皮质激素(原文未给出具体剂量方案)。
- 环磷酰胺组:静脉环磷酰胺脉冲600 mg/m2,于第0、15、30、60天给药,同时给予美司钠(uromitexan)200 mg/m2预防出血性膀胱炎,给药时及4小时后各一次。
- 安慰剂组:对应时间点给予安慰剂。
- 原文结论:不推荐在IPF急性加重患者中使用静脉环磷酰胺脉冲联合糖皮质激素。
红旗征与不能漏的情况
- 总体感染为主要不良事件,环磷酰胺组33%、安慰剂组36%,需监测感染。
研究设计与关键结果
- 研究类型:随机、双盲、安慰剂对照、3期试验,法国31家医院35个科室,纳入120例(环磷酰胺组60例、安慰剂组59例纳入意向性分析),52%为严重IPF。
- 干预:静脉环磷酰胺脉冲600 mg/m2(联合美司钠200 mg/m2)vs 安慰剂,第0、15、30、60天,均联合标准化大剂量糖皮质激素。
- 不良事件:6个月时环磷酰胺组25例(42%)vs 安慰剂组30例(51%),感染环磷酰胺组20例(33%)vs 安慰剂组21例(36%)。
证据类型、等级与局限
- 证据类型:随机双盲安慰剂对照3期试验(RCT)。
对床旁实践的改变
- IPF急性加重患者不应在糖皮质激素基础上加用静脉环磷酰胺脉冲治疗,因3个月死亡率数值上更高(45% vs 31%)。
- 严重IPF患者死亡风险更高,需加强监护;接受机械通气、活动性感染、活动性癌症或等待肺移植者不在本研究范围内,结论不直接适用。
指南或共识出处
- 原文未提及指南或共识名称;试验注册号ClinicalTrials.gov NCT02460588,发表于Lancet Respir Med。
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The use of cyclophosphamide in patients with acute exacerbation of idiopathic pulmonary fibrosis (IPF) is unknown. Our study was designed to evaluate the efficacy and safety of four cyclophosphamide pulses in addition to high-dose methylprednisolone in this population.
METHODS: In this double-blind, placebo-controlled trial done in 35 departments across 31 hospitals in France, adult patients (≥18 years) with acute exacerbation of IPF and those with suspected acute exacerbation of IPF were randomly assigned in a 1:1 ratio using a web-based system to receive either intravenous pulses of cyclophosphamide (600 mg/m2) plus uromitexan as haemorrhagic cystitis prophylaxis (200 mg/m2) at the time of cyclophosphamide administration and then again, 4 h later, or placebo at days 0, 15, 30, and 60. Random assignment was stratified according to the severity of IPF and was block-balanced with variable block sizes of four or six patients. Patients receiving mechanical ventilation, with active infection, with active cancer, or who were registered on the lung transplant waiting list were excluded. All patients received standardised high-dose glucocorticoids. The investigators, patients, and the sponsor were masked to the treatment assignments. The primary endpoint was 3-month all-cause mortality, analysed by a χ2 test adhering to an intention-to-treat principle. The trial is now complete and registered with ClinicalTrials.gov, NCT02460588.
FINDINGS: Between Jan 22, 2016, and July 19, 2018, 183 patients were assessed for eligibility, of whom 120 patients were randomly assigned and 119 patients (62 [52%] with severe IPF) received at least one dose of cyclophosphamide (n=60) or placebo (n=59), all of whom were included in the intention-to-treat analysis. The 3-month all-cause mortality was 45% (27/60) in patients given cyclophosphamide compared with 31% (18/59) in the placebo group (difference 14·5% [95% CI -3·1 to 31·6]; p=0·10). Similar results were found after adjustment by IPF severity (odds ratio [OR] 1·89 [95% CI 0·89-4·04]). The risk of death at 3 months, independent of the treatment received, was higher with severe than non-severe IPF (OR 2·62 [1·12-6·12]) and was lower with the use of antifibrotic therapy (OR 0·33 [0·13-0·82]). Adverse events were similar between groups by 6 months (25 [42%] in the cyclophosphamide group vs 30 [51%] in the placebo group) and their proportion, including infections, did not differ. Overall infection was the main adverse event and occurred in 20 (33%) of 60 patients in the cyclophosphamide group versus 21 (36%) of 59 patients in the placebo group.
INTERPRETATION: In patients with acute exacerbation of IPF, adding intravenous cyclophosphamide pulses to glucocorticoids increased 3-month mortality. These findings provide evidence against the use of intravenous cyclophosphamide in such patients.
FUNDING: Programme Hospitalier de Recherche Clinique of the French Ministry of Health (PHRC 2014-502), Roche Pharmaceuticals.
参考来源
- Naccache JM, Jouneau S, Didier M, et al. Cyclophosphamide added to glucocorticoids in acute exacerbation of idiopathic pulmonary fibrosis (EXAFIP): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2021. PMID: 34506761. doi:10.1016/S2213-2600(21)00354-4
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。